PHASE II STUDY OF 90Y-IBRITUMOMAB TIUXETAN AND FOTEMUSTINE ASSOCIATED WITH CYTARABINE ETOPOSIDE MELPHALAN AS CONDITIONING CHEMORADIOIMMUNOTHERAPY IN PATIENTS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODGKIN) CD20+ REFRACTORY/RELAPSED WITH MINIMAL RESIDUAL PERSISTANT DISEASE PRE-AUTOLOGOUS TRANSPLANT

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2008
This article has no abstract
Epistemonikos ID: aea3304f9bdc7ed87d41df8507369f5759a5e7f3
First added on: Jan 22, 2025